ALX Oncology Holdings Inc. (ALXO)
ALXO Stock Price Chart
Explore ALX Oncology Holdings Inc. interactive price chart. Choose custom timeframes to analyze ALXO price movements and trends.
ALXO Company Profile
Discover essential business fundamentals and corporate details for ALX Oncology Holdings Inc. (ALXO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Jul 2020
Employees
43.00
Website
https://www.alxoncology.comCEO
Jason Lettmann
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
ALXO Financial Timeline
Browse a chronological timeline of ALX Oncology Holdings Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.15.
Earnings released on 8 May 2026
EPS came in at -$0.17 falling short of the estimated -$0.15 by -13.33%.
Earnings released on 27 Feb 2026
EPS came in at -$0.42 falling short of the estimated -$0.38 by -10.53%.
Earnings released on 7 Nov 2025
EPS came in at -$0.41 falling short of the estimated -$0.37 by -10.81%.
Earnings released on 12 Aug 2025
EPS came in at -$0.49 falling short of the estimated -$0.46 by -6.52%.
Earnings released on 8 May 2025
EPS came in at -$0.58 falling short of the estimated -$0.47 by -23.40%.
Earnings released on 6 Mar 2025
EPS came in at -$0.55 surpassing the estimated -$0.72 by +23.61%.
Earnings released on 7 Nov 2024
EPS came in at -$0.58 surpassing the estimated -$0.78 by +25.64%.
Earnings released on 8 Aug 2024
EPS came in at -$0.76 surpassing the estimated -$0.77 by +1.30%.
Earnings released on 9 May 2024
EPS came in at -$0.71 surpassing the estimated -$0.87 by +18.39%.
Earnings released on 7 Mar 2024
EPS came in at -$0.93 falling short of the estimated -$0.84 by -10.71%, while revenue for the quarter reached $2.48m .
Earnings released on 13 Nov 2023
EPS came in at -$1.24 falling short of the estimated -$0.86 by -44.19%.
Earnings released on 10 Aug 2023
EPS came in at -$0.84 surpassing the estimated -$0.85 by +1.18%.
Earnings released on 11 May 2023
EPS came in at -$0.58 surpassing the estimated -$0.84 by +30.95%.
Earnings released on 9 Mar 2023
EPS came in at -$0.60 surpassing the estimated -$0.91 by +34.07%.
Earnings released on 8 Nov 2022
EPS came in at -$0.72 surpassing the estimated -$0.75 by +4.00%.
Earnings released on 8 Aug 2022
EPS came in at -$0.67 falling short of the estimated -$0.66 by -1.52%.
Earnings released on 9 May 2022
EPS came in at -$0.46 surpassing the estimated -$0.77 by +40.26%.
Earnings released on 28 Feb 2022
EPS came in at -$0.56 surpassing the estimated -$0.63 by +11.11%.
Earnings released on 11 Nov 2021
EPS came in at -$0.51 falling short of the estimated -$0.47 by -8.51%.
Earnings released on 12 Aug 2021
EPS came in at -$0.34 surpassing the estimated -$0.42 by +19.05%.
ALXO Stock Performance
Access detailed ALXO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
